Merck & Co., Inc. MRK
Merck remains a hold as the stock's 19% one-month rally on positive Phase 3 cancer vaccine data has pushed valuation into clearly stretched territory — at 124.2x trailing P/E versus a peer median of 33.7x, MRK trades at a 268% premium despite FY2025 revenue growth of just 1.2% and free cash flow that declined to $12.4B from $18.1B. The intismeran autogene/Keytruda melanoma results are a genuine pipeline catalyst, but with RSI at 77.6 and insiders selling into the rally (EVPs disposed shares at $132–135 in mid-August 2026), much of the upside appears priced in.
Total debt at $50.5B against $52.6B equity further limits financial flexibility for additional pipeline investment.
What could go wrong
- Valuation compression. At 124.2x P/E and 31.3x EV/EBITDA — 268% and 36% above peer medians respectively — any disappointment in cancer vaccine timelines or Keytruda LOE mitigation could trigger a sharp de-rating.
- Keytruda patent cliff. Keytruda represents the bulk of Merck's revenue; biosimilar entry post-2028 looms and the pipeline must demonstrate it can replace that revenue stream, yet FY2025 revenue growth slowed to 1.2%.
- Balance sheet deterioration. Total debt surged to $50.5B in FY2025 from $38.3B in FY2024 while FCF fell to $12.4B from $18.1B, constraining capital available for buybacks, dividends, or further acquisitions.
- Overbought technicals. RSI of 77.6 as of 2026-08-25 with the stock at $156.43 versus a 50-day MA of $129.34 suggests near-term mean-reversion risk after the cancer-vaccine-driven rally.
What would change my mind
Where this comes from: peer_relative composite · FMP fundamentals FY2025 vs FY2024 · FMP fundamentals FY2025 · technicals as of 2026-08-25. Orin's read on MRK; not advice.
Twelve months actual closes to 2026-09-23 · actual filings
50-day average 200-day average · volume below
On file
All MRK filingsLargest holders · 13F Q2 2026
Money flow| Filer | Position | Of fund |
|---|---|---|
| Vanguard Capital Management | $20.7B | 0.4% of fund |
| State Street | $15.6B | 0.5% of fund |
| Wellington Management Group Llp | $11.1B | 1.9% of fund |
| Vanguard Portfolio Management | $8.7B | 0.4% of fund |
| Geode Capital Management | $7.8B | 0.4% of fund |
| Charles Schwab Investment Management | $7.0B | 0.9% of fund |
174 filers · quarter ended Q2 2026 · positions, not flows
Insiders, last 24 months: 222 Form 4 filings, net $69.2M. Of the 50 on hand, 0 were open-market purchases and 13 sales— the rest are grants, option exercises and tax withholding.
Ask Orin about MRK
Orin answers questions about MRK from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.
Start 3 free days →Where it trades
| Metric | Now | Own median | Sector |
|---|---|---|---|
| P/E | 117.5× | — | 26.4× |
| EV/EBITDA | 29.8× | 12.3× | — |
| P/S | 5.51× | 4.06× | — |
| P/B | 8.7× | 5.4× | — |
Its P/E sits 80th percentile of its own last 5 years (−0.17σ from its own mean).
13.0%
free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $12.4B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.
What Wall Street published
$158
$105 – $180 · +7% against today's price
- 26 buy or overweight
- 11 hold
- 1 underweight or sell
The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.
Against the companies it is compared to
| Company | Market cap | P/E | EV/EBITDA | Gross | Net | ROE |
|---|---|---|---|---|---|---|
| MRKMerck & Co., Inc. | $366B | 117.5× | 29.8× | 75.4% | 4.8% | 7% |
| ABTAbbott Laboratories | $179B | 33.3× | 20.8× | 56.8% | 11.6% | 11% |
| AMGNAmgen Inc. | $219B | 25.0× | 15.9× | 72.7% | 22.9% | 89% |
| GILDGilead Sciences, Inc. | $188B | — | 331.4× | 79.6% | -10.6% | -16% |
| PFEPfizer Inc. | $161B | 37.2× | 17.6× | 71.3% | 6.8% | 5% |
| TMOThermo Fisher Scientific Inc. | $246B | 35.7× | 26.0× | 41.0% | 15.1% | 13% |
The median is of the 4 peers listed above and nothing else — check it against the column. This company trades 240.6% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.
What it has traded at
What its sector has traded at
Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.
Discounted cash flow
| Model | Fair value | Against | Computed |
|---|---|---|---|
| Standard DCF | $215 | $117.82 · +83% | 2026-06-10 |
| Levered DCF | $121 | $117.82 · +3% | 2026-06-10 |
The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.
Every estimate on one scale
The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.